Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Other solid neoplasm 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Hepatocellular 1Ascites 1Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × danvatirsen × Clear all
NCT02499328 2026-02-11

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

AstraZeneca

Phase 1/2 Completed
340 enrolled 53 charts
Head & NeckOther solid neoplasm

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05814666 2026-01-30

PEMDA-HN

Flamingo Therapeutics NV

Phase 2 Terminated
69 enrolled 21 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
84 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

NCT01839604 2017-03-06

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

AstraZeneca

Phase 1 Completed
58 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡